| scholarly article | Q13442814 |
| P50 | author | Geert Leroux-Roels | Q45380570 |
| Hans Van Vlierberghe | Q92049104 | ||
| P2093 | author name string | Isabelle Desombere | |
| Filip Clinckspoor | |||
| Sibyl Couvent | |||
| P2860 | cites work | Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. | Q43037854 |
| Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C | Q43038103 | ||
| Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice | Q43048089 | ||
| Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial | Q44665741 | ||
| Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma | Q45738869 | ||
| EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver | Q77872085 | ||
| Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay | Q27471213 | ||
| Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum | Q27472747 | ||
| Evaluation of an automated sample preparation protocol for quantitative detection of hepatitis C virus RNA. | Q27473059 | ||
| Performance Evaluation of the VERSANT HCV RNA Qualitative Assay by Using Transcription-Mediated Amplification | Q27473324 | ||
| Multicenter Evaluation of the VERSANT HCV RNA Qualitative Assay for Detection of Hepatitis C Virus RNA | Q27473336 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Clinical implications of hepatitis C viral kinetics | Q33809452 | ||
| Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test. | Q33968828 | ||
| Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics | Q33970328 | ||
| Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests | Q33973999 | ||
| Diagnostic testing for hepatitis C. | Q34006452 | ||
| Hepatitis C kinetics: mathematical modeling of viral response to therapy | Q34006458 | ||
| Automation of laboratory testing for infectious diseases using the polymerase chain reaction-- our past, our present, our future | Q34133115 | ||
| Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy | Q34210668 | ||
| Molecular diagnosis of viral hepatitis | Q34642858 | ||
| Monitoring of viral levels during therapy of hepatitis C. | Q34984089 | ||
| Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance | Q35017795 | ||
| Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA) | Q36240147 | ||
| Hepatitis C: diagnostic assays | Q40402044 | ||
| Factors predictive of a beneficial response to therapy of hepatitis C. | Q40882250 | ||
| Measuring hepatitis C viremia in clinical samples: Can we trust the assays? | Q41523834 | ||
| Therapy of hepatitis C: overview | Q41598802 | ||
| Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. | Q41668553 | ||
| A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus | Q42983656 | ||
| Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa | Q42987319 | ||
| Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. | Q42992298 | ||
| Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays | Q42993978 | ||
| Standardization of hepatitis C virus RNA quantification | Q42999984 | ||
| Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays | Q43000295 | ||
| Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment | Q43035300 | ||
| Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. | Q43036076 | ||
| Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay | Q43036577 | ||
| Viral kinetics of hepatitis C: new insights and remaining limitations | Q43037227 | ||
| Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. | Q43037381 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 2590-2597 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treat | |
| P478 | volume | 43 |
| Q43040666 | Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy |
| Q43039006 | Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA. |
| Q26851978 | Current molecular methods for the detection of hepatitis C virus in high risk group population: A systematic review |
| Q38089735 | Diagnostic markers for hepatitis virus infection |
| Q36517794 | Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection |
| Q43001559 | HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial |
| Q55399966 | Occult Hepatitis C Virus Infection: A Review. |
| Q42979735 | Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections |
| Q51802969 | Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha. |
| Q21089871 | Thermostable DNA polymerase from a viral metagenome is a potent RT-PCR enzyme |
| Q27480934 | Ultracentrifugation of Serum Samples Allows Detection of Hepatitis C Virus RNA in Patients with Occult Hepatitis C |
| Q26777048 | Update on hepatitis B and C virus diagnosis |
| Q27485900 | Variable Patterns of Programmed Death-1 Expression on Fully Functional Memory T Cells after Spontaneous Resolution of Hepatitis C Virus Infection |
| Q50550106 | Vitamins? The magic bullet against hepatitis C. |
Search more.